 |
Publisher: Peytchinski, Gospodin Iliev
ISSN: 1312 773X (Online)
Issue: 2013, vol. 19, book 3;
Subject Collection: Medicine
Page: 476-480
DOI: 10.5272/jimab.2013193.476
Published online: 21 December 2013
J of IMAB. 2013 Jul-Dec;19(3):476-480
OXALIPLATIN/5-FLUOROURACIL/LEUCOVORIN IN THE TREATMENT OF PATIENTS WITH METASTATIC COLORECTAL CANCER
Deyan N. Davidov 
.
Department of Chemotherapy, Oncological center, Medical University, Pleven, Bulgaria.
ABSTRACT:
Objective: Oxaliplatin/ 5- Fluorouracil/ Leucovorin is an effective therapy for patients with metastatic colorectal cancer. The aim of this study was to explore the efficacy and safety of this chemotherapy regimen in the treatment of patient with advanced colorectal cancer.
Methods: From January 2008 to May 2010 twenty six consecutive patients with advanced colorectal cancer entered the study. Treatment schedule consist of intravenous Oxaliplatin 80 mg/m2 on day 1, Leucovorin 200 mg/m2 administered as intravenous infusion on day 1 and 2 and 5- Fluorouracil 400 mg/m2 bolus followed by 5- Fluorouracil 600 mg/m2 as 22- hours infusion with repetition every two weeks.
Results: Overall response rate was 34,6% with one complete response and eight partial responses achieved. The overall survival time was 12,6 months. The main toxicity observed were leukopenia and diarrhea.
Conclusions: That data suggest that chemotherapy with Oxaliplatin/ 5- Fluorouracil/ Leucovorin remain reasonable chemotherapy regimen for the treatment of patients with advanced or metastatic colorectal cancer.
Key words: Chemotherapy; Metastatic colorectal cancer; Survival;
- Download FULL TEXT /PDF 510 KB/
Please cite this article as:
Davidov DN. Oxaliplatin/5-Fluorouracil/Leucovorin in the Treatment of Patients with Metastatic Colorectal Cancer. J of IMAB. 2013 Jul-Dec;19(3):476-480. DOI: 10.5272/jimab.2013193.476.
Correspondence to: Dr Deyan Nikolov Davidov, Department of Chemotherapy, Oncological Center, Medical University; 1, “St. Kliment Ohridsky” Str., 5000 Pleven, Bulgaria; E-mail: dean_davidov@abv.bg;
REFERENCES:
1. Colorectal Cancer Incidence and Mortality Worldwide in 2008. Summary. http://globocan.iarc.fr/factsheets/cancers/colorectal.asp
2. Penna C, Nordlinger B. Colorectal metastasis (liver and lung). Surg Clin North Am. 2002 Oct;82 (5):1075- 1090. [PubMed] [CrossRef]
3. Glimelius B, Hoffman K, Graf W, Pahlman L, Sjoden PO. Quality of life during chemotherapy in patients with symptomatic advanced colorectal cancer. The Nordic Gastrointestinal Tumour Adjuvant Therapy Group. Cancer. 1994 Feb 1;73(3):556–562. [PubMed]
4. Bleiberg H. Role of chemotherapy for advanced colorectal cancer: new opportunities. Semin Oncol, 1996 Feb;23(1 suppl. 3):42-50. [PubMed]
5. Efficacy of IV continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. Meta-analysis Group in Cancer. J Clin Oncol. 1998 Jan;16(1):301–308.
6. Raymond E, Buquet-Fagot C, Djelloul S, Mester J, Cvitcovic E, Allain P, et al. Antitumor activity of oxaliplatin in combination with 5- fluorouracil and the thymidylate synthase inhibitor AG337 in human colon, breast, and ovarian cancers. Anticancer Drugs. 1997 Oct;8(9):876-885. [PubMed]
7. Machover D, Diaz-Rubio E, de Gramont A, Schilf A, Gastiaburu JJ, Brienza S, et al. Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines. Ann Oncol. 1996 Jun;7(1):95-98. [PubMed]
8. Levi F, Perpoint B, Garufi C, Focan C, Chollet P, Depres-Brummer P, et al: Oxaliplatin activity against metastatic colorectal cancer: A phase II study of 5-day continuous venous infusion at circadian rhythm modulated rate. Eur J Cancer, 1993; 29A(9):1280-1284. [PubMed]
9. Diaz-Rubio E, Sastre J, Zaniboni A, Labianca R, Cortez-Funes H, de Braud F, et al. Oxaliplatin as single agent in previously untreated colorectal carcinoma patients: A phase II multicentric study. Ann Oncol. 1998 Jan;9(1):105- 108. [PubMed]
10. Becouarn Y, Ychou M, Ducreux M, Borel C, Bertheault-Cvitkovic F, Seitz JF, et al. Phase II trial of oxaliplatin as first-line chemotherapy in metastatic colorectal cancer patients. J Clin Oncol. 1998 Aug;16(8):2739-2744. [PubMed]
11. de Gramont A, Vignoud J, Tournigand C, Louvet C, Andre T, Varette C, et al. Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer. Eur J Cancer. 1997 Feb;33(2):214-219. [PubMed] [CrossRef]
12. Andre T, Louvet C, Raymond E, Tournigand C, de Gramont A. Bimonthly high-dose leucovorin, 5-fluorouracil 48-hour infusion and oxaliplatin (FOLFOX3) for metastatic colorectal cancer resistant to the same LV-5FU regimen. Ann Oncol. 1998 Nov;9(11):1251-1253. [PubMed]
13. Levi FA, Zidani R, Vannetzel JM, Perpoint B, Focan C, Faggiolo R, et al. Chronomodulated versus fixed infusion rate delivery of ambulatory chemotherapy with oxaliplatin, 5-fluorouracil and folinic acid in patients with colorectal cancer metastases: A randomized multiinstitutional trial. J Natl Cancer Inst. 1994 Nov 2;86(21):1608-1617. [PubMed]
14. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer. 1981 Jan 1;47(1): 207- 214. [PubMed]
15. Brimdage MD, Pater JL, Zee B. Assessing the reliability of two toxicity scales: Implications for interpreting toxicity data. J Natl Cancer Inst. 1993 Jul 21;85(14):38- 48. [PubMed]
16. Kaplan EL, Meier P. Nonparanietric estimationfromincomplete observations. J Amer Statist Assn. 1958 Jun;53:457- 481.
17. de Gramont A, Bosset JF, Milan C, Rougier P, Bouché O, Etienne PL, et al. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. J Clin Oncol. 1997 Feb;15(2):808- 815. [PubMed]
18. de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, et al. Leucovorin and fluorouracil with or without oxaliplatin as first- line treatment in advanced colorectal cancer. J Clin Oncol. 2000 Aug;18(6):2938-2947. [PubMed]
19. Grothey A, Deschler B, Kroening H. Bolus 5- fluorouracil (5-FU)/ folinic acid (FA) Mayo vs weekly high dose 24- h 5- FU infusion/ FA + oxaliplatin (OXA) in advanced colorectal cancer (CRC): Results of a phase III study. Proc Am Soc Clin Oncol. 2001; 20:125a, abstr 496.
20. de Gramont A, Bosset JF, Milan C, Rougier P, Bouché O, Etienne PL, et al. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. J Clin Oncol. 1997 Feb;15(2):808- 815. [PubMed]
21. Seymour MT, Slevin ML, Kerr DJ, Cunningham D, James RD, Ledermann JA, et al. Randomized trial assessing the addition of interferon alpha-2a to fluorouracil and leucovorin in advanced colorectal cancer. Colorectal Cancer Working Party of the United Kingdom Medical Research Council. J Clin Oncol. 1996 Aug;14(8):2280-2288. [PubMed].
Accepted for publication: 11 October 2013
Published online: 21 December 2013